Eiger Biopharmaceuticals Inc Revenue Growth Rates (EIGR), Current and Historic Growth - CSIMarket
CSIMarket Company Name, Ticker, Suppliers, else..
 


• Revenue Y/Y
• Op. Income Y/Y
• Cop. Income Y/Y
• Net Income Y/Y
• Eps Cop. Y/Y
• Eps Net Y/Y
• Free Cash Flow Y/Y
• Cash Flow Y/Y
• Capex Y/Y
• Sales Y/Y Annual
Eiger Biopharmaceuticals Inc   (NASDAQ: EIGR)
 

EIGR's Revenue Growth by Quarter and Year

Eiger Biopharmaceuticals Inc 's Revenue results by quarter and year



Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

EIGR Revenue (in millions $) FY 2023 FY 2022 FY 2021 FY 2020
4th Quarter December 3.80
3rd Quarter September 3.21
2nd Quarter June 4.64
1st Quarter March 4.12
FY 15.77





EIGR Revenue fourth quarter 2023 Y/Y Growth Comment
Eiger Biopharmaceuticals Inc achieved in the fourth quarter 2023, above Company average Revenue rise of 40.85% year on year, to $ 3.80 millions.

Looking into fourth quarter 2023 results within Biotechnology & Pharmaceuticals industry 23 other companies have achieved higher Revenue growth. While Eiger Biopharmaceuticals Inc ' s Revenue jump of 40.85% ranks overall at the positon no. 545 in the fourth quarter 2023.


EIGR Revenue ( Y/Y Growth %) 2023
 2022 2021 2020
4th Quarter December 40.85 % -19.64 % - -
3rd Quarter September -20.15 % 32.24 % - -
2nd Quarter June 13.45 % 94.76 % - -
1st Quarter March 54.31 % -26.85 % - -
FY   17.01 % 10.95 % - -

Financial Statements
Eiger Biopharmaceuticals Inc 's fourth quarter 2023 Revenue $ 3.80 millions EIGR's Income Statement
Eiger Biopharmaceuticals Inc 's fourth quarter 2022 Revenue $ 2.70 millions Quarterly EIGR's Income Statement


EIGR Revenue (Quarter on Quarter Growth %)

 2023
 2022 2021 2020
4th Quarter December 18.47 % -32.84 % 10.53 % -
3rd Quarter September -30.82 % -1.71 % 44.76 % -
2nd Quarter June 12.62 % 53.18 % -42.47 % -
1st Quarter March 52.59 % -20.54 % - -
FY (Year on Year)   17.01 % 10.95 % - -


Back to EIGR Growth rate Comparisons >> Back to EIGR Growth rate Comparisons >>


Revenue fourth quarter 2023 Y/Y Growth Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry #24
Healthcare Sector #147
Overall #545

Revenue Y/Y Growth Statistics
High Average Low
95.09 % 21.18 % -26.69 %
(Jun 30 2022)   (Mar 31 2022)
Revenue fourth quarter 2023 Y/Y Growth Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry #24
Healthcare Sector #147
Overall #545
Revenue Y/Y Growth Statistics
High Average Low
95.09 % 21.18 % -26.69 %
(Jun 30 2022)   (Mar 31 2022)

Revenue by Quarter for the Fiscal Years 2020, 2021, 2022, 2023

Eiger Biopharmaceuticals Inc 's Q/Q Revenue Growth


Revenue Q/Q Growth Statistics
High Average Low
53.05 % 5.83 % -42.48 %
(Jun 30 2022)  


EIGR's IV. Quarter Q/Q Revenue Comment
Eiger Biopharmaceuticals Inc achieved in the IV. Quarter 2023 above company average sequential Revenue jump of 18.47%, to $ 3.80 millions, from $3.21 millions in the third quarter.
EIGR is undergoing a remarkable growth, with claiming higher then normal increase, and additionally increasing rate.

Within Biotechnology & Pharmaceuticals industry 20 other companies have achieved higher Revenue quarter on quarter growth. While Eiger Biopharmaceuticals Inc 's Revenue growth quarter on quarter, overall rank is 566.


Revenue Q/Q Growth Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry #21
Healthcare Sector #115
Overall #566
Revenue Q/Q Growth Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry #21
Healthcare Sector #115
Overall #566
Revenue Q/Q Growth Statistics
High Average Low
53.05 % 5.83 % -42.48 %
(Jun 30 2022)  


EIGR's IV. Quarter Q/Q Revenue Comment
Eiger Biopharmaceuticals Inc achieved in the IV. Quarter 2023 above company average sequential Revenue jump of 18.47%, to $ 3.80 millions, from $3.21 millions in the third quarter.
EIGR is undergoing a remarkable growth, with claiming higher then normal increase, and additionally increasing rate.

Within Biotechnology & Pharmaceuticals industry 20 other companies have achieved higher Revenue quarter on quarter growth. While Eiger Biopharmaceuticals Inc 's Revenue growth quarter on quarter, overall rank is 566.


Eiger Biopharmaceuticals Inc 's 12 Months Revenue Growth Year on Year


Revenue TTM Growth

12 Months Ending
(Dec 31 2023)		 12 Months Ending
(Sep 30 2023)		 12 Months Ending
(Jun 30 2023)		 12 Months Ending
(Mar 31 2023)		 12 Months Ending
(Dec 31 2022)
Cumulative Revenue 12 Months Ending $ 15.77 $ 14.67 $ 15.48 $ 14.93 $ 13.48
Y / Y Revenue Growth (TTM) 16.98 % 3.66 % 17.61 % 33.66 % 11.05 %
Year on Year Revenue Growth Overall Ranking # 1242 # 1180 # 1293 # 1290 # 1256
Seqeuential Revenue Change (TTM) 7.55 % -5.26 % 3.7 % 10.72 % -4.69 %
Seq. Revenue Growth (TTM) Overall Ranking # 2707 # 1431 # 969 # 2358 # 2881


Cumulative Revenue growth Comment
Eiger Biopharmaceuticals Inc saw improvement in Revenue growth trend, posting cumulative 12 months Revenue growth of 16.98% year on year, to $ 16 millions if the fiscal year would have ended in Dec 31 2023.
Eiger Biopharmaceuticals Inc 's trailing twelve months Revenue growth was higher than company's average 16.59% and higher than 3.66% growth in Sep 30 2023.
But from twelve months ended Sep 30 2023 rise was beneth at 7.55 % from $14.67 millions achieved in the period from Sep 30 2023 to Dec 31 2022.
We witness drop-off happening, more obvious observing the usual Q/Q TTM historic rise that is stronger at16.59%.
The momentum is even more impressive from twelve months ended Sep 30 2023 exhibited at 7.55 % increase from $14.67 millions in the period from Sep 30 2023 to Dec 31 2022.

In the Healthcare sector 248 other companies have achieved higher trailing twelve month Revenue growth. While Revenue growth total ranking has deteriorated compare to previous quarter from 1180 to 1242.

Revenue TTM Y/Y Growth Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry # 41
Healthcare Sector # 249
Overall # 1242

Revenue TTM Y/Y Growth Statistics
High Average Low
33.66 %
 16.59 %
3.66 %
 


Revenue TTM Q/Q Growth Company Ranking
Within: No.
Industry # 41
Sector # 403
S&P 500 # 2707
Cumulative Revenue growth Comment
Eiger Biopharmaceuticals Inc saw improvement in Revenue growth trend, posting cumulative 12 months Revenue growth of 16.98% year on year, to $ 16 millions if the fiscal year would have ended in Dec 31 2023.
Eiger Biopharmaceuticals Inc 's trailing twelve months Revenue growth was higher than company's average 16.59% and higher than 3.66% growth in Sep 30 2023.
But from twelve months ended Sep 30 2023 rise was beneth at 7.55 % from $14.67 millions achieved in the period from Sep 30 2023 to Dec 31 2022.
We witness drop-off happening, more obvious observing the usual Q/Q TTM historic rise that is stronger at16.59%.
The momentum is even more impressive from twelve months ended Sep 30 2023 exhibited at 7.55 % increase from $14.67 millions in the period from Sep 30 2023 to Dec 31 2022.

In the Healthcare sector 248 other companies have achieved higher trailing twelve month Revenue growth. While Revenue growth total ranking has deteriorated compare to previous quarter from 1180 to 1242.


Revenue TTM Y/Y Growth Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry # 41
Healthcare Sector # 249
Overall # 1242

Revenue TTM Y/Y Growth Statistics
High Average Low
33.66 %
16.59 %
3.66 %
 


Revenue TTM Q/Q Growth Company Ranking
Within: No.
Industry # 41
Sector # 403
S&P 500 # 2707




Other Revenue Growth
Biotechnology & Pharmaceuticals Industry Revenue Growth Trends and Statistics
Healthcare Sector Revenue Growth Statistics
Revenue Growth Trends for overall market
EIGR's Revenue Growth Ratio versus Biotechnology & Pharmaceuticals Industry, Healthcare Sector and total Market
Highest Ranking Revenue Growth
Lowest Ranking Revenue Growth




Companies with similar Revenue jump for the quarter ending Dec 31 2023 within Healthcare SectorY/Y Change %Revenue for the quarter ending Dec 31 2023
Esperion Therapeutics Inc 71.38%$ 71.378 millions
Electrocore Inc 71.37%$ 71.367 millions
Cvrx inc 70.81%$ 70.805 millions
Acadia Pharmaceuticals Inc 69.27%$ 69.273 millions
Elite Pharmaceuticals Inc 68.64%$ 68.637 millions
Bicycle Therapeutics Plc67.38%$ 67.378 millions
Beone Medicines Ltd 66.91%$ 66.908 millions
Axim Biotechnologies Inc 66.79%$ 66.790 millions
Cyclo Therapeutics Inc 66.70%$ 66.699 millions
Agios Pharmaceuticals Inc 64.80%$ 64.803 millions
Orthofix Medical Inc 64.24%$ 64.245 millions
Mannkind Corporation62.16%$ 62.156 millions
Dianthus Therapeutics Inc 61.87%$ 61.872 millions
Prosomnus Inc 61.36%$ 61.357 millions
Lumos Pharma Inc 61.33%$ 61.328 millions
Inspiremd Inc 59.75%$ 59.747 millions
Lifemd Inc 59.53%$ 59.532 millions
Aurinia Pharmaceuticals Inc 58.59%$ 58.590 millions
Bioxcel Therapeutics Inc 57.98%$ 57.983 millions
Marizyme Inc 57.39%$ 57.386 millions
Spero Therapeutics Inc 54.98%$ 54.978 millions
Sarepta Therapeutics Inc 53.54%$ 53.537 millions
Tela Bio Inc 53.10%$ 53.102 millions
Biodesix Inc 52.68%$ 52.680 millions
Theralink Technologies Inc 51.82%$ 51.820 millions
Intra cellular Therapies Inc 50.34%$ 50.336 millions
Avita Medical Inc 50.13%$ 50.132 millions
Calliditas Therapeutics Ab49.74%$ 49.741 millions
Innoviva Inc 49.70%$ 49.701 millions
Rosecliff Acquisition Corp I49.10%$ 49.104 millions


About Eiger Biopharmaceuticals Inc Revenue Growth Rates (EIGR), Current and Historic Growth - CSIMarket Analysis

How we calculate this

This page is based on issuer-reported fundamentals and CSIMarket’s U.S. equities database (20+ years). Growth is computed using year-over-year (Y/Y), sequential, and trailing-twelve-month (TTM) methods.

What’s included here

Company: Eiger Biopharmaceuticals Inc (CIK 1305253).

Source & verification

Last updated

  • Page updated:
  • Data lineage: SEC filings → XBRL parse → normalization CSIMarket.com Database → growth calculations.
  • Accession: 0001628280-24-015297
  • Figures are derived from filed reports and may be restated; numbers are subject to revision.

Sources: Eiger Biopharmaceuticals Inc ’s SEC filings (XBRL/Inline XBRL) and CSIMarket.com’s normalization & QA processes.



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.